Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22604
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Williams, David S | - |
dc.contributor.author | Mouradov, Dmitri | - |
dc.contributor.author | Newman, Marsali R | - |
dc.contributor.author | Amini, Elham | - |
dc.contributor.author | Nickless, David K | - |
dc.contributor.author | Fang, Catherine G | - |
dc.contributor.author | Palmieri, Michelle | - |
dc.contributor.author | Sakthianandeswaren, Anuratha | - |
dc.contributor.author | Li, Shan | - |
dc.contributor.author | Ward, Robyn L | - |
dc.contributor.author | Hawkins, Nicholas J | - |
dc.contributor.author | Skinner, Iain | - |
dc.contributor.author | Jones, Ian | - |
dc.contributor.author | Gibbs, Peter | - |
dc.contributor.author | Sieber, Oliver M | - |
dc.date | 2020-02-11 | - |
dc.date.accessioned | 2020-02-18T22:28:57Z | - |
dc.date.available | 2020-02-18T22:28:57Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.citation | Modern Pathology 2020; 33(7): 1420-1432 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/22604 | - |
dc.description.abstract | Mucinous colorectal adenocarcinoma (CRC) is conventionally defined by extracellular mucin comprising >50% of the tumour area, while tumours with ≤50% mucin are designated as having a mucinous component. However, these definitions are largely arbitrary and comparisons of clinico-molecular features and outcomes by proportion of mucinous component are limited. A cohort of 1643 patients with stage II/III cancer was examined for tumour mucinous component, DNA mismatch repair (MMR) status, BRAF mutation and tumour infiltrating lymphocytes (TILs). Tumours with ≤50% mucinous component exhibited similar characteristics as mucinous tumours, including association with female gender, proximal location, high grade, TIL-high, defective MMR (dMMR) and BRAF mutation. Proportion of mucinous component did not stratify disease-free survival (DFS). In univariate analysis dMMR status, but not histological grade, stratified survival for mucinous and mucinous component tumours; however, in multivariate analysis dMMR status was not an independent predictor. BRAF mutation prognostic value depended on mucinous differentiation and MMR status, with poor prognosis limited to non-mucinous pMMR tumours (HR 2.61, 95% CI 1.69-4.03; p < 0.001). TIL status was a strong independent predictor of DFS in mucinous/mucinous component tumours (HR 0.40, 95% CI 0.23-0.67; p < 0.001), and a superior predictor of prognosis compared with histological grade, MMR and BRAF mutation. Mucinous component and mucinous stage II/III CRCs exhibit clinico-molecular resemblances, with histological grade and BRAF mutation lacking prognostic value. Prognosis for these tumours was instead strongly associated with TIL status, with the most favourable outcomes in TIL-high dMMR tumours, whilst TIL-low tumours had poor outcomes irrespective of MMR status. | - |
dc.language.iso | eng | - |
dc.title | Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | - |
dc.identifier.affiliation | Clinipath Pathology, Sonic Healthcare, Perth, WA, Australia | en |
dc.identifier.affiliation | Department of Surgery, Royal Melbourne Hospital, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Department of Surgery, Western Health, Footscray, VIC, Australia | en |
dc.identifier.affiliation | Melbourne Pathology, Cabrini Health, Malvern, VIC, Australia | en |
dc.identifier.affiliation | Department of Pathology, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Personalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Prince of Wales Clinical School and Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia | en |
dc.identifier.affiliation | Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia | en |
dc.identifier.affiliation | School of Medical Sciences, UNSW Sydney, Sydney, NSW, Australia | en |
dc.identifier.affiliation | Faculty of Medicine, The University of Queensland, Herston, QLD, Australia | en |
dc.identifier.affiliation | Department of Medical Oncology, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Department of Medical Oncology, Western Health, Footscray, VIC, Australia | en |
dc.identifier.affiliation | Department of Surgery, The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | School of Biomedical Sciences, Monash University, Clayton, VIC, Australia | en |
dc.identifier.doi | 10.1038/s41379-020-0496-1 | - |
dc.identifier.orcid | 0000-0001-9480-0786 | - |
dc.identifier.pubmedid | 32047231 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Newman, Marsali R | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Pathology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.